Outset Medical, Inc.
In their words
“Industry leading retention rates above 90% at 90 days”
“On a scale from 1 indicating not likely to 10 indicating extremely likely to recommend Tablo, the study showed a mean Net Promoter Score of 9.2 at 6 months and 9.3 at 12 months.”
“90-plus percent of patients who dialyze at home with Tablo remain on treatment at 90 days”
NPS disclosures (1)
On a scale from 1 indicating not likely to 10 indicating extremely likely to recommend Tablo, the study showed a mean Net Promoter Score of 9.2 at 6 months and 9.3 at 12 months.
Retention disclosures (5)
Retention rate (home): 90% (Q4 2024) — “industry leading retention rates above 90% at 90 days”
Retention rate (home): 90% (Q1 2024) — “90-plus percent of patients who dialyze at home with Tablo remain on treatment at 90 days”
Churn (home end market (Tablo patients)): 10% (Q2 2023) — “our retention rate continued to perform well with Tablo's patient operate consistently hovering in the 10% range”
Churn: 50% (12 months) — “at 12 months, the controllable attrition rate excluding death or transplant is nearly 50% lower than what is reported in the USRDS database”
Churn: 15% (Q2 2022) — “observing about a 15% rate of death and transplant a combination of death and transplant”
Lighthouse companies in Pharma, medtech & health distribution
About these figures
Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.
NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.